Tip os
Log ind

Qualcomm chief: This is the future

Top picks in English:

The General Manager of the healthcare division in Qualcomm, the world’s largest wireless technology group, offers his view on how healthcare technology will evolve in the future.


by Leonora Beck
Offentliggjort 20.05.14 kl. 14:31

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Former William Demant CFO joins German rehab giant

Stefan Ingildsen.jpg Top picks in English:

A former Chief Financial Officer from hearing device maker William Demant takes over as finance chief for one of the biggest rehabilitation care companies in the world.

”It’s professional speed dating for life science”

Top picks in English:

Stockholm is currently hosting the biggest dating event for life science companies in the Nordic countries. A number of Danish players have very clear objectives for the event.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Novo’s science chief says he is not letting go of the Holy Grail

Top picks in English:

Although Novo Nordisk has discontinued its activities in what CSO Mads Krogsgaard Thomsen has previously called the Holy Grail of diabetes care, he is not resigned to letting go completely. A partnership with the world’s most cited researcher could bring Novo back in the game. But for now, he has turned his attention to another Holy Grail.

Novo and Lundbeck post millions in new Danish biotech company

Top picks in English:

Lundbeckfond Emerge and Novo Seeds have teamed up with Capnova to invest millions in a new Danish biotech company, spun off from Aarhus University. Meanwhile, the startup has brought a prominent capacity from the US into its boardroom.

Novo Nordisk jumps on the discount wagon

Top picks in English:

Novo Nordisk’s US unit has struck a deal with CVS Health for a new savings program that will give some patients up to 80 percent reduction on some of the group’s insulin products. It thus looks like times are changing in the Denmark-based insulin giant.

Forsiden lige nu

Nye fremskridt i løvens biologiske sats

Kim Kjøller LEO Pharma.jpg Medicinal & Biotek:

Biotekselskabet Argenx har klaret sig helskindet igennem det prækliniske arbejde på det stof, som Leo Pharma har investeret i. Næste stop er fase 1. Godt for det biologiske sats, lyder det fra forskningsdirektør Kim Kjøller.

De første studieresultater: Overvægtige taber sig med Novo Nordisks fedmehåb

Medicinal & Biotek:

Novo Nordisk fører an i jagten på at udvikle medicin, som kan smelte kilo af overvægtige kroppe. Spritnye resultater for GLP-1-analogen Semaglutid viser de første gode takter for medicinalkoncernens næste fedmehåb. (opdateret)

Novo Seeds investerer millioner i potentielt guldæg

Medicinal & Biotek:

Nyt biotekselskab, der udspringer fra Københavns Universitet, har fået 20 mio. kr. fra Novo Seeds til at udvikle lægemiddel til behandling af diabetes, fedme og fedtlever.

Lundbeck-direktør: Jeg var klar over, at FDA så det på en anden måde

Medicinal & Biotek:

Om Lundbeck vil forsøge en tredje gang at få udvidet indlægssedlen på antidepressivet Trintellix i USA er endnu uvist, siger forskningsdirektør Anders Gersel Pedersen for hvem, nattens afslag fra FDA ikke var en fuldstændig overraskelse.

Novo står til længe ventet labelopdatering i Europa

Medicinal & Biotek:

Novo Nordisk er godt på vej til at kunne medtage data fra det vigtige hjerte-kar-studie Leader i indlægssedlen for diabetesblockbusteren Victoza i Europa efter en positiv anbefaling fra CHMP.

FDA puster til patentstrid med ny godkendelse

Medicinal & Biotek:

De amerikanske lægemiddel-myndigheder har godkendt den første behandling af sjælden sygdom, der kan administreres af patienten selv. Det sker midt i patentslagsmål med midlet som centrum.

ANNONCE
ANNONCE


ANNONCE